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Abstract 
 
Purpose 
To report on the composition and performance of the portfolio of Ophthalmology research 
studies in the United Kingdom’s National Institute for Health Research (NIHR) Clinical 
Research Network (UK CRN). 
 
Methods 
Ophthalmology studies open to recruitment between 1 April 2010 and 31 March 2018 were 
classified by: subspecialty, participant age, gender of Chief Investigator, involvement of 
genetic investigations, commercial/ non-commercial, interventional/observational design. 
Frequency distributions for each covariate and temporal variation in recruitment to time and 
target were analysed. 
 
Results 
Over 8 years, 137,377 participants were recruited (average of 15,457 participants/year; 
range: 5,485 to 32,573) with growth by year in proportion of commercial studies and hospital 
participation in England (76% in 2017/18). Fourteen percent of studies had a genetic 
component and most studies (82%) included only adults. The majority of studies (41%) 
enrolled patients with retinal diseases, followed by glaucoma (17%), anterior segment and 
cataract (13%), and ocular inflammation (6%). Overall, 68% of non-commercial studies and 
55% of commercial studies recruited within the anticipated time set by the study and also 
recruited to or exceeded the target number of participants.  
 
Conclusions 
High levels of clinical research activity, growth and improved performance have been 
observed in Ophthalmology in the UK over the past eight years. Some subspecialties that 
carry substantial morbidity and a very high burden on NHS services are underrepresented 
and deserve more patient-centred research. Yet the NIHR and its CRN Ophthalmology 
National Specialty Group has enabled key steps in achieving the goal of embedding 
research into every day clinical care.  
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Introduction 
 
The National Institute for Health Research (NIHR) has transformed research in the United 
Kingdom’s National Health Service (NHS) since its establishment in 2006. It has increased 
the volume of applied health research for the benefit of patients and the public, driven faster 
translation of basic science discoveries into tangible benefits for patients and the economy, 
and developed and supported the people who conduct and contribute to applied health 
research.  The Health and Social Care Act 2012 places a statutory duty to promote research, 
and powers to support it, on the Secretary of State and on all levels of the NHS including 
NHS England, and Clinical Commissioning Groups.1 
 
The NIHR provides the support and facilities the NHS needs for first-class research by 
funding a range of infrastructure facilities (Figure 1). An integral part of this structure is the 
Clinical Research Network (CRN, received core funding of £302.4 million in 2017/18 from 
UK Government’s NIHR allocation of £1 billion) which provides infrastructure and facilitates 
participation in research.  
 
The NIHR CRN is responsible for creating and maintaining the UK CRN portfolio, a 
collection of high-quality clinical studies, many of which are randomized controlled trials.2 
Only studies included in this database have access to infrastructure and NHS service 
support costs offered by the NIHR CRN. NHS service support costs are the costs associated 
with those tasks which are being undertaken for patient care, but would not be part of 
standard care i.e. are not a part of the treatment or regime and end when the research ends. 
This includes tasks such as extra blood tests, or extra nurse appointments to monitor safety 
during a trial, but they also cover “ethical safety” such as making sure informed consent is 
achieved for all participants. The processing of patient records and subsequent mailing 
activities are considered as NHS service support costs because they make certain that 
patients are offered the chance to participate only in research opportunities for which they 
are potentially eligible. 
 
The CRN is divided across the 15 regions of England (termed Local Clinical Research 
Networks, LCRNs) and supports the set-up and timely delivery of commercial and non-
commercial studies in the NHS. Ophthalmologists and optometrists representing each of 
these regions along with nominated leads for Wales, Scotland, and Northern Ireland 
(Appendix 1 Supplementary materials) comprise the NIHR CRN Ophthalmology National 
Specialty Group. 
 
[in-margin link as follows 
https://www.rcophth.ac.uk/professional-resources/research-hub/the-nihr-ophthalmology-
clinical-research-network/the-nihr-ophthalmology-specialty-group/  ] 
 
The NIHR CRN Ophthalmology National Specialty Group (NSG) oversees, monitors and 
supports the delivery of Ophthalmology portfolio studies on the UK CRN portfolio. Since the 
inception of the National Specialty Groups, the Ophthalmology NSG has created a portfolio 
which has shown steady growth of both commercial and non-commercial studies and put in 
place measures to overcome barriers to patient recruitment, and as a consequence high 
proportions of the portfolio studies have recruited to time and to target (i.e, recruitment of 
total sample size within the timeframe specified by the chief investigator of the study) as a 
measure of performance. 
  
In the present report, the NIHR Ophthalmology NSG examines the Ophthalmology portfolio 
performance in detail to better understand the composition of research undertaken, activity 
by hospital Trust, sources of funding and the gender balance of the leaders of the projects.3  
 
 
 4
 
Methods 
 
Supported by the NIHR’s Business Intelligence Unit (K.B), the database of the UK CRN 
portfolio was accessed and Ophthalmology studies that had been open to recruitment at any 
time between 1 April 2010 and 31 March 2018 were selected.4 Studies that had closed to 
recruitment prior to 1 April 2010 were not included as in the early phase of creation of the 
UK CRN portfolio, details of commercial studies in particular were incompletely captured. As 
Ophthalmology encompasses a wide range of topics each study was classified by 
subspecialty by two researchers (SD and EL) with specialist knowledge of vision science.  
The study protocol was scrutinised and in the event of discordance in assigning the sub-
specialty classification, a third researcher (RB) arbitrated. Studies were also categorised 
according to participant age (adults or paediatric or both), and by the gender of the Chief 
Investigator of the studies. Finally, studies were grouped into those that involved genetic 
investigations and those that did not. Studies on the portfolio were also classified as 
commercial or non-commercial and by design into interventional or observational studies. 
Frequency distribution charts were prepared. 
 
 
Results 
 
Over 7 years between 1 April 2010 and 31 March 2018, 137377 participants were recruited 
into Ophthalmology portfolio studies across the UK, with an increase in numbers recruited 
from 5,485 participants in 2010/2011 to 16182 in 2017/18 (Figure 2). An average of 15,457 
participants were recruited per year (range: 5,485 to 32,573). Recruitment in 2013/2014 was 
particularly high at 32,573 participants on account of a single cohort commercial study into 
which 19,100 people were recruited. Fifty-two studies were entered onto the portfolio in 
2010/2011, increasing to 72 in 2017/18, the majority of studies were non-commercial with a 
non-commercial:commercial ratio that ranged between 3.3:1 in 2012/2013 and 1.4:1 in 
2016/17. The contribution of commercial studies to the total number of studies per year 
increased during this time period. More studies were observational in design than 
interventional with an observational:interventional ratio that ranged between 1.4:1 and 0.7:1 
for these year points.  
 
In 2017/2018, 76% (86 of 113) of hospitals with acute eye care services in England were 
recruiting into at least one NIHR portfolio Ophthalmology study. This figure had increased 
from 2016/2017 (69%) and 2015/16 (57%). The number of participants recruited in each of 
the 15 English LCRNs over the 8 year period ranged from 1838 to 36266. The English 
LCRN figures are presented alongside recruitment among the devolved nations of the UK in 
Figure 3. The highest-recruiting region was North-West Coast, recruiting 36,266 participants 
(one particular study recruited 19100 participants [study ID 14595]), followed by 24,509 
participants recruited in the North Thames region, the location of the only Biomedical 
Research Centre dedicated solely to Ophthalmology, the NIHR Moorfields Biomedical 
Research Centre.   
 
Eighty studies (13.8%) had a genetic component.  The majority of studies (81.7%) included 
adults only. Forty-two studies included children and 64 included both adults and children. 
 
Examining the subspecialty distribution within Ophthalmology (Figure 4), the majority of 
studies (41%) enrolled patients with diseases of the retina, followed by glaucoma (17%), 
anterior segment and cataract (13%), and ocular inflammation (6%). Of the retinal studies 
the principal disease groups were age-related macular degeneration (13% of all studies), 
diabetic retinopathy (9%) and inherited retinopathy (6%). Studies of thyroid eye disease 
were included in the ‘Other’ category. 
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By subspecialty there were differences in temporal trends in terms of both absolute numbers 
and proportion of studies from the different sub specialties over the period of enquiry 
(Appendix 2 Supplementary materials).  The number and proportion of studies of diseases of 
the retina rose over time. Although the numbers of studies were lower in the other 
subspecialties, there was a steady increase in the anterior segment and cataract group. 
Studies of neuro-ophthalmology and glaucoma remained relatively static, while those 
dealing with ocular inflammation studies declined slightly.  
 
Over the 8 year time period, there were differences between subspecialties in terms of the 
non-commercial:commercial study ratio. For example, ocular inflammation studies had more 
commercial involvement (0.9:1), compared to other subspecialties such as glaucoma (2.3:1), 
retina(1.7:1) and anterior segment and cataract (2.4:1). There were no commercial refraction 
and optometry studies. There was a gradual increase in the proportion of retina studies that 
are commercial compared to non-commercial between 2010/11 (6 studies: 9 studies) and 
2016/17 (16:14), falling marginally in 2017/2018 (10:14).  
 
Funders of studies in the portfolio are presented in Figure 5. Among non-commercial studies 
(Figure 5a) Fight for Sight (FFS) was responsible for funding approximately 15-30% of 
studies in each of the years examined, with the NIHR funding a further 10-35%.  Funders of 
commercial studies are given in Figure 5b. 
 
Across the 8-year period from 2010/11 to 2017/18, 68% of non-commercial studies recruited 
within the anticipated time set by the study and also recruited to or exceeded the target 
number of participants set by the study. For commercial studies this figure was 55%. This 
overall figure disguises the improvement in achieving recruitment to time and target over this 
period which is presented in Appendix 3 Supplementary materials. For example in the past 6 
years, the recruitment to time and target for non-commercial and commercial studies has 
been 71% and 58%, respectively. A proportion of those studies that missed both time and 
recruitment targets were ‘near-misses’, where studies achieved 90-100% in respect either of 
time or target or both. 21% of non-commercial studies and 27% of commercial studies that 
missed 100% target were ‘near-misses’, over the 8 year period. 
 
The gender of the Chief Investigator was known for 379 studies. The trend across the years 
for proportion of male or female chief investigators are shown in Appendix 4 Supplementary 
materials. Overall, there were more male chief investigators for every year analysed. For 
example, a third of studies in 2017/18 were led by a female chief investigator. There was no 
clear trend over the study period in this gender imbalance. 
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Discussion 
 
Clinical research in the UK is essential for improving care for patients, for example by 
providing evidence on the efficacy of new healthcare treatments. The NIHR aims to increase 
the opportunities for patients and the public to participate in, and benefit from, research. 
Ophthalmology is clearly a very active research area within the UK CRN portfolio, recruiting 
an average of 15,000 patients into clinical trials within the NHS per year, with consistent 
growth over the past 7 years. The majority of hospitals (76%) that deliver acute eye care 
services are participating in recruitment of patients to UK CRN Ophthalmology studies yet 
there are hospitals which are still not involved. Increasing hospital participation has been a 
focus (‘Specialty Objective’) of the NIHR Ophthalmology NSG in recent years. 
Ophthalmology remains the single busiest out-patient specialty in hospitals in the UK (for 
example, there are a million out-patient visits for glaucoma per year5). It is therefore 
important that patients have access to the benefits of clinical research that include new 
medications, devices, and diagnostic technology. Ophthalmology departments also benefit 
from participation in UK CRN portfolio studies with funding allocation available for staff and 
training.  With the advent of online clinical trial search systems (eg. UK Clinical Trials 
Gateway)6 there has been a growing awareness among patient groups of potential ocular 
research projects, and a drive from patients and their carers to seek out trials relevant to 
their ocular disease. Recent reports involving bowel cancer survival7 have demonstrated that 
hospitals that engage in clinical research have better outcomes. This may well also be the 
case for Ophthalmology and underscores the need to encourage involvement of the 
remaining 24% (2017/18 data) of UK Ophthalmology Departments who are not currently 
participating in UK CRN Ophthalmology Portfolio studies. The work of the NIHR 
Ophthalmology NSG in encouraging more involvement by the Royal College of 
Ophthalmologists in integrating research into clinical care through a number of initiatives that 
include regular symposia at College congresses, web-based resources for all clinicians, and 
awards to highly active and inspirational clinical researchers and trainees, has undoubtedly 
contributed to awareness of the Ophthalmology portfolio and its growth. This has also been 
assisted by regular review of the portfolio of commercial and non-commercial studies with 
the NIHR Portfolio Management team (E.C) to maximise recruitment to open studies and to 
detect studies in difficulty early and target support.  
 
in-margin link to the aforementioned webpages 
https://www.rcophth.ac.uk/professional-resources/research-hub/the-nihr-ophthalmology-
clinical-research-network/  
 
Financial benefits of participation in NHS research are substantial. A report by KPMG 
estimated that for commercial studies, NHS Trusts receive an average of £6,658 per patient 
in revenue from sponsor companies, and a pharmaceutical cost saving of £5,250 per patient 
recruited to each clinical study.8 This equated to estimated totals of £176 million of 
commercial income and £16 million of pharmaceutical cost savings across the commercial 
CRN Portfolio in 2014/15. Our analysis has demonstrated the importance of commercial 
involvement in the funding of Ophthalmology clinical studies. The proportion of studies that 
are commercial was small in the early years of the Ophthalmology NSG yet a drive to 
increase means this proportion has risen to a third of the Ophthalmology study portfolio. 
Another aim of the NIHR is to maximise the research potential of the NHS to contribute to 
the economic growth of the country through the life science industry.9 We have seen a 
gradual increase in the proportion of commercial studies, particularly in the category of 
retinal disease, when compared to numbers of non-commercial studies over this time period. 
Ocular inflammation studies also have a significant commercial involvement. However, this 
analysis has shown that in some subspecialty areas such as glaucoma and anterior 
segment and cataract, commercial investment in UK CRN portfolio studies is much less 
marked. Given the contribution of these two disease groups respectively to vision 
impairment10 and ocular morbidity11 , and the substantial commercial interests in these 
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diseases, further commercially-funded research development in these areas would be 
welcome. Ophthalmology remains a leader among other specialties within the UK in terms of 
research into novel research areas such as gene therapies12, novel drug delivery systems13, 
robotic surgery14 and artificial intelligence,15 all of which have enormous growth potential.  
 
Non-commercial funding for Ophthalmology research is a major challenge within the UK. In 
a report published by The Macular Society, of a total of £2025.2 million spent by charities, 
research councils and government on health research, only £22.7 million was spent on eye 
research in 2014. Despite there being considerable turnover by sight loss charities per year 
(£774.5 million income in 2014), there was a relatively small financial contribution to UK 
research within this sector, the largest donor being Fight for Sight, which contributed £3.6 
million of a total of £9.6 million spent by sight loss charities on UK medical research in 
2014.16 Closer collaboration between patient groups, eyecare charities and the research 
community to build on prior work to identify key research priorities is underway; an excellent 
example of this is the James Lind Alliance where stakeholders (patients, carers, third sector, 
Ophthalmologists, Optometrists) came together to categorise research priorities in a series 
of meetings. Innovative partnerships to boost research funding through commercial, 
philanthropic and charitable sources need to be explored, in order for research into eye 
disease to match the success of other UK-based research pipelines as seen in cancer and 
diabetes research. Sensory organ diseases rank seventh in the global ranking of DALYs by 
cause.17 We should be aiming to ensure that research funding matches this high health 
burden ranking. Cross-cutting research that considers the impact of eye disease and vision 
impairment on related disease areas, for example, cognitive decline and frailty, and 
comorbidities may augment the importance of eye research in the eyes of potential funders. 
A recent focus of the NIHR has been to assess whether research is active in areas of the 
greatest need. In our analysis of numbers of Ophthalmology study recruits/100,000 
population (Figure 3) it is clear that there is wide geographical variation in research 
participation even when discounting North Thames (given the presence of a Biomedical 
Research Centre devoted to vision science in that location). With the development of 
networks of Ophthalmology electronic record systems such as the National Ophthalmology 
Database,18 UK Ophthalmology has the potential to better understand its areas of met need. 
However, without accurate population-based data on distribution of eye disease and its risk 
factors we are unable to map research activity to areas of greatest need. This is the 
rationale for the UK National Eye Health Survey which is currently in preparation.  
NIHR CRN and its Ophthalmology NSG has shown itself capable of delivering very large 
multicentre studies across the UK that benefit from NIHR support costs which have had very 
significant national and international impact on patient outcomes.19-25 This demonstrates that 
UK centres work together cohesively to produce high quality research. The NIHR has 
contributed to the development and strengthening of these networks, providing local and 
national guidance, as well as fostering and encouraging close working partnerships with the 
third sector and commercial entities. These studies require very substantial organisation of 
the infrastructure at each of these hospital sites for the duration of each study. Retention of 
this infrastructure to rapidly deliver further studies at these sites is a major focus of the NIHR 
Ophthalmology NSG drawing on experiences of other networks in other countries which 
have pipelines of research protocol development, funding streams and research delivery.26 
Ten years ago, studies were scrutinised by members of the NIHR Ophthalmology NSG prior 
to inclusion onto the portfolio for quality, presence of a clear research question and 
relevance to the NHS and to ensure that funding was in place. In 2014 this process was 
streamlined to only involve studies that were not funded by automatically eligible funding 
streams. From the point of securing funding and making the application for inclusion, the 
time taken to recruit has also reduced with improvements to the governance processes (this 
was also attributable to the work of the NIHR CRN teams who developed the pathways and 
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standard procedures to facilitate streamlined progression through ethics and NHS Research 
and Development hospital trust approvals. The targeting of NIHR CRN resources to non-
research active centres allowed these NHS units to participate. Strategic support to specific 
clinical sites (often guided by the NIHR Ophthalmology NSG during the recruitment phase of 
failing studies) has helped dramatically turn round many of these studies. The recruitment to 
time and target presented in Appendix 3 (Supplementary Materials) demonstrates this 
improvement within Ophthalmology studies over the last 8 years yet there is still room for 
improvement, particularly with commercial studies. 
The high participation rate of Ophthalmology departments (79% in 2017/18) in hospitals 
across the UK demonstrates the willingness of ophthalmologists, optometrists, ophthalmic 
technicians and nurses to get involved in these interesting and innovative studies. The 
Health and Social Care Act of 2012 placed a statutory duty to promote research in the NHS 
and the Ophthalmology community have demonstrated how clinical research can be 
successfully embedded into clinical care. The Royal College of Physicians’ ‘Research for All’ 
report identified areas which could be improved in order to maximise participation.27 One of 
these areas may involve exploring the gender differences in research activity, a part of which 
was reflected in our finding that there were fewer female Chief Investigators among NIHR 
Ophthalmology portfolio studies than men. This ratio for the years 2015/16 (3.5:1) and 
2016/17 (1.5:1) is not that different to the ratio of male:female ophthalmology consultants in 
the UK in 2016, which has been reported as 2.8:1.28 Several reports have identified under-
representation of women in medical research.29 Another area of development sponsored by 
the NIHR Ophthalmology NSG has been the development of Ophthalmology Trainee 
Research Networks which have successfully developed large multicentre studies and are 
continuing to expand across the UK.30 Direct experience of clinical studies by trainees, often 
working as principal investigators, prepares them early in their careers to integrate research 
into clinical care. 
 
In conclusion, this analysis has demonstrated high levels of clinical research activity in the 
field of Ophthalmology and its subspecialties over the past eight years, with enthusiastic 
participation by hospital departments, their staff and their patients across the UK. The study 
highlights some subspecialties of Ophthalmology that carry substantial morbidity and a very 
high burden on NHS services which do not currently attract the clinical research studies and 
commercial interest that they deserve.  More patient-centred research into these areas and 
a more coordinated approach to matching research activity to need are areas of ongoing 
development. However, it is important to note that the first key steps in achieving the goal of 
embedding research into every day clinical care have been enabled by NIHR and that the 
Ophthalmic specialist network appears to work well with increases of participant recruitment 
year on year across all four nations of the UK. 
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Figure 1: Infrastructure Facilities funded by the NIHR (reproduced with permission of 
NIHR)  
 
 
 
Figure 2. Numbers of participants recruited into NIHR CRN Ophthalmology portfolio 
studies in the UK by year, with categorisation into commercial and non-commercial 
sponsorship, and by design (observational/interventional/both)   
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Figure 3. Numbers of participants (and number recruited per 100,000 population) 
recruited into UK CRN Ophthalmology portfolio studies in each of the 15 Local 
Clinical Research Networks and the devolved nations between 1 April 2010 and 31 
March 2018.  
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Figure 4. Numbers of UK CRN Ophthalmology portfolio studies classified by 
subspecialty that were open between April 2010 and 31 March 2018. 
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